Ascentage pharma announces closing of us$75 million equity investment by takeda

Rockville, md. and suzhou, china , june 20, 2024 /prnewswire/ -- ascentage pharma (6855.hk), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis b (chb), and age-related diseases, announced today that the agreed equity investment by takeda has been closed on june 20, 2024, with all proceeds already received.
TAK Ratings Summary
TAK Quant Ranking